168 related articles for article (PubMed ID: 18538039)
1. Advances in mouse models of prostate cancer.
Ahmad I; Sansom OJ; Leung HY
Expert Rev Mol Med; 2008 Jun; 10():e16. PubMed ID: 18538039
[TBL] [Abstract][Full Text] [Related]
2. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
Kasper S
J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647
[TBL] [Abstract][Full Text] [Related]
3. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
[TBL] [Abstract][Full Text] [Related]
4. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
5. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
[TBL] [Abstract][Full Text] [Related]
6. Androgen-dependent prostate epithelial cell selection by targeting ARR(2)PBneo to the LPB-Tag model of prostate cancer.
Wang Y; Kasper S; Yuan J; Jin RJ; Zhang J; Ishii K; Wills ML; Hayward SW; Matusik RJ
Lab Invest; 2006 Oct; 86(10):1074-88. PubMed ID: 16894353
[TBL] [Abstract][Full Text] [Related]
7. Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
Lee DH; Yu EJ; Aldahl J; Yang J; He Y; Hooker E; Le V; Mi J; Olson A; Wu H; Geradts J; Xiao GQ; Gonzalgo ML; Cardiff RD; Sun Z
PLoS One; 2019; 14(1):e0211153. PubMed ID: 30677079
[TBL] [Abstract][Full Text] [Related]
8. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression.
Olson A; Le V; Aldahl J; Yu EJ; Hooker E; He Y; Lee DH; Kim WK; Cardiff RD; Geradts J; Sun Z
PLoS Genet; 2019 Oct; 15(10):e1008451. PubMed ID: 31658259
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
10. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.
Lee SH; Luong R; Johnson DT; Cunha GR; Rivina L; Gonzalgo ML; Sun Z
Oncogene; 2016 Feb; 35(6):702-14. PubMed ID: 25893287
[TBL] [Abstract][Full Text] [Related]
11. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
12. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
13. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
[TBL] [Abstract][Full Text] [Related]
14. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
15. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer.
Kasper S; Smith JA
J Urol; 2004 Jul; 172(1):12-9. PubMed ID: 15201729
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
[TBL] [Abstract][Full Text] [Related]
17. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
[TBL] [Abstract][Full Text] [Related]
18. Mutation of the androgen receptor causes oncogenic transformation of the prostate.
Ratliff TL
J Urol; 2005 Sep; 174(3):1149. PubMed ID: 16094083
[No Abstract] [Full Text] [Related]
19. Metformin targets c-MYC oncogene to prevent prostate cancer.
Akinyeke T; Matsumura S; Wang X; Wu Y; Schalfer ED; Saxena A; Yan W; Logan SK; Li X
Carcinogenesis; 2013 Dec; 34(12):2823-32. PubMed ID: 24130167
[TBL] [Abstract][Full Text] [Related]
20. Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.
Hafeez BB; Fischer JW; Singh A; Zhong W; Mustafa A; Meske L; Sheikhani MO; Verma AK
Cancer Prev Res (Phila); 2015 May; 8(5):375-86. PubMed ID: 25627799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
